Home | Emory University

Infectious Diseases Clinical Research Consortium (IDCRC)

Infectious Diseases Clinical Research Consortium

Slide 1:
Slide 2:
Slide 3:

The Infectious Diseases Clinical Research Consortium (IDCRC) and Vaccine and Treatment Evaluation Units (VTEUs) work in tandem with the National Institute of Allergy and Infectious Diseases (NIAID) as a coordinated national and global network of scientific experts working to develop and test vaccines and other therapies to combat infectious diseases.

NIH Announces Launch of Fifth Large-Scale COVID-19 Vaccine Trial

Phase 3 trial of Novavax investigational COVID-19 vaccine opens and will enroll volunteers at IDCRC/VTEU sites

NIH News

COVID-19 Vaccine Appears Well-Tolerated and Effective in Developing Antibodies in Small Study of Older Adults

COVID-19 Prevention Network

The CoVPN was established by merging four existing NIAID-funded clinical trials networks: the HIV Vaccine Trials Network; the HIV Prevention Trials Network; the Infectious Diseases Clinical Research Consortium; and the AIDS Clinical Trials Group.

More about the CoVPN

COVID-19 Prevention Network launches two research studies evaluating monoclonal antibodies

SUPPORT OF CLINICAL RESEARCH FOR 2019 NOVEL CORONAVIRUS (SARS-COV-2) & DISEASE (COVID-19)

The novel coronavirus 2019-nCoV, SARS-CoV-2, pandemic continues to expand and the IDCRC is working with NIAID to conduct clinical research into the treatment and prevention of infections (COVID-19) caused by this virus. What we know about COVID-19 and SARS-CoV-2 is constantly changing. To stay up-to-date on the most current information about how the epidemic is impacting the world, we recommend that you visit the following websites for reliable and accurate information.

View Resources

VTEU COVID-19 Trials

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

In this small study involving older adults, adverse events associated with the mRNA-1273 vaccine were mainly mild or moderate.

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Letter to the New England Journal of Medicine (NEJM) editor from NIAID, IDCRC and VTEU investigators

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Peer-reviewed report on Moderna COVID-19 vaccine: published data from the Phase 3 clinical trial supported by IDCRC-VTEU sites confirming vaccine is effective

Baricitinib plus remdesivir shows promise for treating COVID-19

In a randomized, controlled trial of more than 1,000 adults hospitalized with COVID-19 pneumonia, treatment with the anti-inflammatory drug baricitinib resulted in faster recovery and a greater likelihood of clinical improvement, when combined with the antiviral drug remdesivir.

About

The IDCRC works through a flexible, sustaining structure to advance new countermeasures and approaches to product development, implement efficient clinical study/trial designs, and support exceptional career development and mentoring of future leaders in infectious diseases clinical research. The consortium's collective experience and access to diverse populations give it the ability to evaluate new vaccines and therapies for infectious diseases.

IDCRC Active & Completed Studies